Novel |
PTN |
pleiotrophin |
- Signaling by ALK
- Signaling by ALK
- MDK and PTN in ALK signaling
- MDK and PTN in ALK signaling
|
|
|
Novel |
PTPN11 |
protein tyrosine phosphatase non-receptor type 11 |
- Interleukin-6 signaling
- PI3K Cascade
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- GPVI-mediated activation cascade
- Prolactin receptor signaling
- PIP3 activates AKT signaling
- Spry regulation of FGF signaling
- Signaling by SCF-KIT
- GAB1 signalosome
- Downstream signal transduction
- PECAM1 interactions
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signaling by Leptin
- Co-inhibition by CTLA4
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Netrin mediated repulsion signals
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Regulation of IFNG signaling
- RET signaling
- Interleukin-20 family signaling
- MET activates PTPN11
- Regulation of RUNX1 Expression and Activity
- Interleukin-37 signaling
- Activated NTRK2 signals through FRS2 and FRS3
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- FLT3 Signaling
- STAT5 Activation
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Co-inhibition by BTLA
|
|
- Metachondromatosis
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
Novel |
PTPRZ1 |
protein tyrosine phosphatase receptor type Z1 |
- Other interleukin signaling
- MDK and PTN in ALK signaling
|
|
|
Novel |
RASA1 |
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
Novel |
SHC1 |
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
Novel |
SHC3 |
SHC adaptor protein 3 |
- Signalling to RAS
- Signalling to RAS
- RAF/MAP kinase cascade
- RET signaling
|
|
|
Novel |
SMC1A |
structural maintenance of chromosomes 1A |
- Meiotic synapsis
- Separation of Sister Chromatids
- Establishment of Sister Chromatid Cohesion
- Cohesin Loading onto Chromatin
- Resolution of Sister Chromatid Cohesion
- SUMOylation of DNA damage response and repair proteins
- Estrogen-dependent gene expression
|
|
- Cornelia de Lange syndrome (CdLS)
|
Novel |
TNFRSF8 |
TNF receptor superfamily member 8 |
- TNFs bind their physiological receptors
|
- Iratumumab
- XmAb 2513
- Brentuximab vedotin
|
|
Novel |
TSPAN16 |
tetraspanin 16 |
|
|
|
Novel |
TTC19 |
tetratricopeptide repeat domain 19 |
|
|
- Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
|
Novel |
ZC3HC1 |
zinc finger C3HC-type containing 1 |
- Nuclear events stimulated by ALK signaling in cancer
|
|
|
|
APBB1 |
amyloid beta precursor protein binding family B member 1 |
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
|
|
BIRC6 |
baculoviral IAP repeat containing 6 |
- ALK mutants bind TKIs
- Signaling by ALK fusions and activated point mutants
|
|
|
|
CLNS1A |
chloride nucleotide-sensitive channel 1A |
|
|
|
|
DLG2 |
discs large MAGUK scaffold protein 2 |
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Neurexins and neuroligins
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
|
|
|
DNMT3A |
DNA methyltransferase 3 alpha |
- PRC2 methylates histones and DNA
- RMTs methylate histone arginines
- SUMOylation of DNA methylation proteins
- DNA methylation
- Defective pyroptosis
- Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
|
|
|
|
DUSP19 |
dual specificity phosphatase 19 |
|
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Myoepithelial Cells
- Developmental Lineage of Mammary Stem Cells
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Pancreatic cancer
- Gastric cancer
- Ovarian cancer
- Choriocarcinoma
- Endometrial Cancer
- Bladder cancer
|
|
HADHB |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
- Acyl chain remodeling of CL
- Beta oxidation of myristoyl-CoA to lauroyl-CoA
- mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
- Beta oxidation of palmitoyl-CoA to myristoyl-CoA
- Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
- Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
- Beta oxidation of octanoyl-CoA to hexanoyl-CoA
- Beta oxidation of hexanoyl-CoA to butanoyl-CoA
|
|
|
|
HES1 |
hes family bHLH transcription factor 1 |
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- RUNX2 regulates osteoblast differentiation
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|